O141: Managing HIV-HCV co-infection

UNITAID can address HCV/HIV co-infection.

In the fi rst days of March, the governing body of UNITAID, the organisation fi nanced mainly through a levy on air tickets, will decide on a new 4-year strategy. A 5-year evaluation praised UNITAID’s success ful “market impact” model for improving access to HIV, tuberculosis, and malaria products through lower ing prices, improving supply, or introducing new products. We believe UNITAID’s new ...

Hiv-1/hcv Co-infection: Immunity and Viral Dynamics

HIV-HCV Co-Infection among Multitransfused Thalassemic Individuals-A Review

Human immunodeficiency virus (HIV) and Hepatitis B and C virus (HBV and HCV) are three most common chronic viral pathogens among multitransfused thalassemic major individuals. HCV and HIV consist of a positive single stranded RNA genome, whereas HBV is a partially double stranded DNA virus. These viruses have similar routes of transmission, namely through blood and blood products, sharing of ne...

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.

Hepatitis C virus (HCV) is the cause of more than three-quarters of liver-related deaths in HIV-seropositive individuals and it is remarkable that today approximately one-quarter of HIV-infected individuals in Europe and the USA have a HCV coinfection. HIV/HCV coinfected patients were more likely to develop cirrhosis, had an increased risk of developing AIDS, of HIV-related disease and of overa...

Antiretroviral Therapy in HIV/HCV Co-Infection Italian Consensus Workshop

About 50% of people living with the HIV infection in Italy are co-infected with HCV. In this group of patients, the primary cause of mortality is liver disease, which accounts for up to 14% of deaths. HIV/HCV co-infection also exposes patients to a higher risk of progression to AIDS, a faster evolution towards cirrhosis, more frequent drug toxicity, and lower tolerance for antiretroviral therap...